Extended-release trazodone in the treatment of major depressive disorder

KARAMUSTAFALIOĞLU K. O., Dilbaz N., ÇAYKÖYLÜ A., ALKIN T., GÖNÜL A. S., ATMACA M.

ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, cilt.20, sa.5, ss.453-459, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 20 Sayı: 5
  • Basım Tarihi: 2019
  • Doi Numarası: 10.5455/apd.302644467
  • Dergi Adı: ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.453-459
  • Anahtar Kelimeler: major depressive disorder, extended-release trazodone (single dose of TzCOAD per day), immediate-release trazodone (three doses of TzIR per day)
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Major depressive disorder is a common psychiatric disorder. The aim of the treatment is to improve daily functions with remissions in symptoms, and antidepressants are the first-line treatments for a major depressive episode (moderate-severe depressive episode). In this paper, the pharmacological properties, clinical efficacy and safety of extended-release trazodone (TzCOAD) are studied. Expert opinion: A single daily dose of TzCOAD may provide similar efficacy and increased tolerability to immediate-release trazodone (TzIR) and other antidepressants.